Apply on Employer Site

Halia Therapeutics, Inc. · 1 day ago

DIRECTOR OF SEC REPORTING

Lehi, UT

Full-time

Hybrid

Director/Executive

$160K/yr - $185K/yr

10+ years exp

Halia Therapeutics, Inc. is preparing for its transition to a public company, and they are seeking a Director of SEC Reporting to lead this critical initiative. The role involves building the SEC reporting function, ensuring compliance with public company standards, and collaborating with various stakeholders to facilitate the IPO process.

BiotechnologyMedicalNeurosciencePharmaceutical

Responsibilities

Lead the build-out of Halia’s SEC reporting function in preparation for an IPO, including drafting registration statement financials and related disclosures

Prepare and review external financial reporting materials, including IPO filings (e.g., S-1) and subsequent periodic SEC reports (10-Q, 10-K, 8-K) post-IPO

Own financial statement preparation, footnotes, and MD&A in accordance with U.S. GAAP and SEC requirements

Establish scalable processes and timelines to support accurate, timely, and high-quality external reporting

Partner closely with Legal, Investor Relations, and Executive Leadership to ensure consistent and clear financial messaging across filings, investor materials, and public disclosures

Monitor emerging accounting standards and SEC rules; assess impact and lead implementation

Design and implement a SOX-ready internal control framework, including risk assessment, control design, documentation, and initial testing

Collaborate with the Corporate Controller to formalize accounting policies and procedures aligned with public company best practices

Serve as a primary liaison with external auditors, IPO advisors, and other external consultants

Support the CFO and senior leadership on technical accounting matters, equity and financing transactions, and other strategic initiatives

Assist in building and mentoring the SEC reporting and controls capability as the company scales

Qualification

SEC reportingU.S. GAAPInternal controlsIPO readinessTechnical accountingLeadershipCommunication skillsCollaboration

Required

Bachelor's degree in Accounting, Finance, or related field

CPA required

10+ years of progressive accounting experience, including leadership in SEC reporting and technical accounting

Strong technical expertise in U.S. GAAP, SEC reporting requirements, and internal controls

Proven ability to build processes from the ground up in a fast-paced, evolving environment

Excellent written and verbal communication skills with strong attention to detail

Effective cross-functional collaborator with a pragmatic, solutions-oriented mindset

Preferred

Public accounting background strongly preferred

Biotech or life sciences experience a plus

Prior experience supporting IPO readiness and/or operating as a newly public company is highly desirable

Benefits

Annual bonus opportunity

Meaningful equity participation

Comprehensive benefits program

Company

Halia Therapeutics, Inc.

Halia is a clinical-stage biopharmaceutical company discovering and developing novel therapies to improve the lives of patients with inflammatory disorders and neurological diseases.

Founded in 2017

Lehi, Utah, USA

11-50 employees